• Citer

Equal IgG antibody response to pneumococcal vaccination in all stages of human immunodeficiency virus disease.

par Vandenbruaene, M.;Colebunders, R;Mascart, Françoise ;Haerden, Y;Van Hove, D;Peeters, Martine;Goeman, J;Van Royen, P;Avonts, D
Référence The Journal of infectious diseases, 172, 2, page (551-553)
Publication Publié, 1995-08

Article révisé par les pairs

• Détails
• Contenu

Résumé :

To evaluate the immunogenicity and safety of a 23-valent pneumococcal vaccine in human immunodeficiency virus (HIV)-seropositive patients, 80 men and 18 women received 1 dose of the vaccine (Pneumo 23; Pasteur Mérieux MSD, Brussels). The total IgG antibody response against all 23 Streptococcus pneumoniae capsular antigens was measured. Antibody levels were expressed in arbitrary units per microliter, referring to a standard curve. Geometric mean titers of the total IgG capsular antibodies on the day of vaccination and 30-45 days later were compared. The ratios of titers after and before vaccination in patients with > 500, 200-500, and < 200 CD4 lymphocytes/microL were 10, 10, and 12.6, respectively. Nonresponse (ratio < 4) occurred in 17% of patients and was unrelated to CD4 cell count. The vaccine was well tolerated; no serious side effects occurred. In 83% of the patients with HIV infection, the total antipneumococcal IgG level was higher after vaccination.